Market closedNon-fractional

Arvinas/ARVN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Arvinas

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Ticker

ARVN

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

New Haven, United States

Employees

445

Arvinas Metrics

BasicAdvanced
$2B
Market cap
-
P/E ratio
-$5.90
EPS
1.95
Beta
-
Dividend rate
$2B
1.95
4.943
4.885
0.18
0.426
-20.78%
-63.32%
24.335
3.25
3.25
-4.874
-48.11%
4.49%
50.16%
21.42%

What the Analysts think about Arvinas

Analyst Ratings

Majority rating from 20 analysts.
Buy

Arvinas Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-274.30% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$25M
-67.77%
Net income
-$69M
-81.11%
Profit margin
-274.30%
-41.38%

Arvinas Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 31.57%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
-$1.18
-$2.53
-$0.97
-
Expected
-$1.65
-$1.58
-$1.27
-$1.42
-$0.86
Surprise
-24.19%
-25.12%
99.55%
-31.57%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arvinas stock?

Arvinas (ARVN) has a market cap of $2B as of July 25, 2024.

What is the P/E ratio for Arvinas stock?

The price to earnings (P/E) ratio for Arvinas (ARVN) stock is 0 as of July 25, 2024.

Does Arvinas stock pay dividends?

No, Arvinas (ARVN) stock does not pay dividends to its shareholders as of July 25, 2024.

When is the next Arvinas dividend payment date?

Arvinas (ARVN) stock does not pay dividends to its shareholders.

What is the beta indicator for Arvinas?

Arvinas (ARVN) has a beta rating of 1.95. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Arvinas stock

Buy or sell Arvinas stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing